The majority of staffers and executives in the biotech and pharmaceutical industries disapprove of the FDA's approval of Biogen's Alzheimer's drug aducanumab, according to survey results released June 9 by Endpoints News.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,